Overexpression of HER2 is associated with disease prognosis and has been observed in approximately 25%–30% of breast cancers, 6%–35% of gastric cancers, 9%–32% of ovarian cancers, and 25%–78% of prostate cancers (3). Here, ERBB2 is linked to breast cancer.